Glaxo profits fall amid Avandia blow

Drugs giant GlaxoSmithKline today reported a £147m (€165.5m) hit after writing off stocks of its controversial diabetes drug Avandia.

Glaxo profits fall amid Avandia blow

Drugs giant GlaxoSmithKline today reported a £147m (€165.5m) hit after writing off stocks of its controversial diabetes drug Avandia.

European regulators last month suspended Avandia and further strict restrictions were placed on its US sales following evidence linking the treatment to an increased risk of heart attack.

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited